| Quote
: |
李硕熙,梁雪松,李鑫峰,赵敏.健脾温肾方治疗腹泻型肠易激综合征临床疗效及对血清T淋巴细胞亚群的影响[J].湖南中医药大学学报英文版,2017,37(7):785-788.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 2151times Download 513times |
| 健脾温肾方治疗腹泻型肠易激综合征临床疗效及对血清T淋巴细胞亚群的影响 |
| 李硕熙,梁雪松,李鑫峰,赵敏 |
| (黑龙江中医药大学佳木斯学院, 黑龙江 佳木斯 154007;黑龙江中医药大学研究生院, 黑龙江 哈尔滨 150040) |
| 摘要: |
| 目的 观察健脾温肾方对腹泻型肠易激综合征的临床疗效及对血清T淋巴细胞亚群的影响。方法 将符合纳入标准的患者59例随机分为2组，其中对照组29例，治疗组30例，对照组给予匹维溴铵治疗，治疗组在对照组的基础上给予健脾温肾方治疗，2组患者疗程均为4周，并随访8周。分别观察2组治疗前后临床症状积分、大便Bristol评分、生活质量评分（IBS-QOL、SF-36）、血清T淋巴细胞亚群及随访的复发率。结果 对照组总有效率为89.7%，治疗组为93.3%，两组比较差异具有统计学意义（P<0.05）。两组治疗后Bristol评分明显降低（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）；IBS-QOL、SF-36评分明显升高（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）；CD4+、CD4+/CD8+水平与治疗前比较均明显升高（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）；CD8+水平与治疗前比较均明显升高（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）。对照组随访复发率为34.5%，治疗组为10%，对照组复发率明显高于治疗组（P<0.05）。结论 健脾温肾方能显著缓解IBS-D患者临床症状及改善大便性质及生活质量，提高患者的免疫功能，复发率低，且无明显不良反应。 |
| 关键词: 腹泻型肠易激综合征 健脾温肾方 临床疗效 T淋巴细胞亚群 |
| DOI：10.3969/j.issn.1674-070X.2017.07.023 |
| Received:February 20, 2017 |
| 基金项目: |
|
| Effect of Jianpi Wenshen Decoction on Clinical Symptoms and Serum T Lymphocyte Subsets in Patients with Diarrhea-Predominant Irritable Bowel Syndrome |
| LI Shuoxi,LIANG Xuesong,LI Xinfeng,ZHAO Min |
| (Jiamusi College, Heilongjiang University of Chinese Medicine, Jiamusi, Heilongjiang 154007, China;Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China) |
| Abstract: |
| Objective To observe the effect of Jianpi Wenshen (invigorating spleen and warming kidney) decoction on clinical symptoms and serum T lymphocyte subsets in patients with diarrhea-predominant irritable bowel syndrome. Methods The 59 cases of patients were randomly divided into 2 groups according to the diagnostic criteria and inclusion criteria, including 29 cases in the control group and 30 cases in the treatment group. The control group was treated with pinaverium bromide and the treatment group was received with Jianpi Wenshen decoction on the basis of control group. Both groups were treated for 4 weeks and followed up for 8 weeks. The clinical symptom score, Bristol score, quality of life score (IBS-QOL, SF-36), serum T lymphocyte subsets and recurrence rate. Results The total effective rate of control group was 89.7%, the total effective rate of treatment group was 93.3%, differences between the two groups were statistically significant (P<0.05). Bristol scores were significantly improved compared with before treatment in both groups (P<0.05), and the difference was statistically significant between the two groups (P<0.05). IBS-QOL and SF-36 scores were significantly improved compared with before treatment (P<0.05), there was significant difference between the two groups (P<0.05). The CD4+ and CD4+/CD8+ levels significantly increased compared with before treatment (P<0.05), the difference was statistically significant between the two groups (P<0.05). The CD8+ level was significantly higher than before treatment (P<0.05), the difference was statistically significant between the two groups (P<0.05). The recurrence rate of the control group was 34.5%, the treatment group was 10%, the recurrence rate of the control group was significantly higher than that of the treatment group, the difference was statistically significant (P<0.05). Conclusion Jianpi Wenshen decoction could significantly relieve the clinical symptoms, improve the quality of stool, quality of life and the immune function, and the recurrence rate was low with no significant adverse reaction. |
| Key words: diarrhea-predominant irritable bowel syndrome Jianpi Wenshen decoction clinical efficacy T lymphocyte subsets |
|
二维码（扫一下试试看！） |
|
|
|
|
